Literature DB >> 15990433

Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report.

Anthony Glasper1, Michael McDonough, Jenny Bearn.   

Abstract

The emergence of gamma-hydroxybutyrate (GHB) dependence in the UK is described, with specific reference to a case study of serial episodes of GHB withdrawal. Symptoms are broadly similar to those for alcohol withdrawal, and rapid deterioration into delirium is common in severe dependence. This case report reflects the variability in clinical presentation of GHB withdrawal and response to treatment, even within the same patient. It is concluded that GHB withdrawal requires vigorous clinical management, preferably on an elective basis, in an inpatient setting if dependence is severe.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990433     DOI: 10.1159/000085551

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  4 in total

Review 1.  Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion.

Authors:  Y Grace Wang; Todd J Swick; Lawrence P Carter; Michael J Thorpy; Neal L Benowitz
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

2.  Gamma-hydroxybutyrate withdrawal syndrome: a case report.

Authors:  Michael A Kuiper; Nicole Peikert; E Christiaan Boerma
Journal:  Cases J       Date:  2009-03-25

Review 3.  Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.

Authors:  Rama M Kamal; Martijn S van Noorden; Wim Wannet; Harmen Beurmanjer; Boukje A G Dijkstra; Arnt Schellekens
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

Review 4.  Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.

Authors:  Lawrence P Carter; Daniel Pardi; Jane Gorsline; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-06-02       Impact factor: 4.492

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.